Conclusion
Myocarditis appears to be an unpredictable and relatively infrequent side effect following vaccination with COVID-19 mRNA vaccines, is most common in younger males and appears to be self-limiting with supportive therapy. This is relevant to the ongoing public debate regarding proposals for vaccination of children under the age of 16, in whom the balance of benefit and risk may be more finely balanced(
21). Our findings may also contribute to the debate regarding booster vaccine doses in those with prior documented myocarditis episodes. Ongoing monitoring using large scale national reporting systems is essential for both the prevalence and relevance of post-vaccine myocarditis to be truly understood.